Table Info

Genotype	n	Frequency
ε2/ε2	0	0.00%
ε2/ε3	24	13.48%
ε3/ε3	116	65.17%
ε2/ε4	9	5.06%
ε3/ε4	19	10.67%
ε4/ε4	10	5.62%
Total	178	-

Declarations

Acknowledgments

We thank the participants of the studies who made this study possible. We are thankful to all the employees of Fujirebio HD group for their generous help, especially we thank Kazuyuki Umeda, Mario Denoyette, Jarne Delanote, and Maarten De Jonge for their efforts to develop the ApoE kits.

Author contributions

TY: Resources, Data curation, Investigation, Methodology, Writing—review & editing. RD: Resources, Data curation, Methodology, Writing—review & editing. DM: Resources, Methodology, Writing—review & editing. HS: Resources, Data curation, Investigation, Writing—review & editing. JK and TN: Resources, Investigation, Methodology. IV and KA: Supervision, Writing—review & editing. HN: Data curation, Formal analysis, Supervision, Investigation, Visualization, Writing—original draft, Project administration, Writing—review & editing.

Conflicts of interest

TY, HS, JK, TN, and HN are employees of Fujirebio Inc. TY, RD, DM, and IV are employees of Fujirebio Europe N.V. KA is a board member of Fujirebio Inc.

Ethical approval

Study procedures were compliant with the principles of the Declaration of Helsinki. The ethics committee approved the study at H.U. Group Holdings, Inc. in the 2022 fiscal year (22-012-01).

Consent to participate

Informed consent to participate in the study was obtained from participants.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106–18. [DOI] [PubMed] [PMC]

Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921–3. [DOI] [PubMed]

Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349–56. [DOI] [PubMed]

Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol. 2011;10:241–52. [DOI] [PubMed] [PMC]

Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis. 2022;9:197–210. [DOI] [PubMed]

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388:9–21. [DOI] [PubMed]

Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S, et al. Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis. 2022;9:221–30. [DOI] [PubMed] [PMC]

Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10:362–77. [DOI] [PubMed] [PMC]

Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F. Amyloid-related imaging abnormalities and β-amyloid-targeting antibodies: a systematic review. JAMA Neurol. 2022;79:291–304. [DOI] [PubMed]

10.

Siest G, Pillot T, Régis-Bailly A, Leininger-Muller B, Steinmetz J, Galteau MM, et al. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem. 1995;41:1068–86. [DOI] [PubMed]

11.

Calero O, Hortigüela R, Bullido MJ, Calero M. Apolipoprotein E genotyping method by real time PCR, a fast and cost-effective alternative to the TaqMan^® and FRET assays. J Neurosci Methods. 2009;183:238–40. [DOI] [PubMed]

12.

Zhong L, Xie YZ, Cao TT, Wang Z, Wang T, Li X, et al. A rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism. Mol Neurodegener. 2016;11:2. [DOI] [PubMed] [PMC]

13.

Dupuy AM, Badiou S, Ritchie K, Mas E, Descomps B, Cristol JP, et al. Discrepancies between apolipoprotein E phenotyping and genotyping in the elderly. Clin Chem Lab Med. 2001;39:405–13. [DOI] [PubMed]

14.

Kataoka S, Paidi M, Howard BV. Simplified isoelectric focusing/immunoblotting determination of apoprotein E phenotype. Clin Chem. 1994;40:11–3. [DOI] [PubMed]

15.

Uchida Y, Ito S, Nukina N. Sandwich ELISA for the measurement of Apo-E4 levels in serum and the estimation of the allelic status of Apo-E4 isoforms. J Clin Lab Anal. 2000;14:260–4. [DOI] [PubMed] [PMC]

16.

Niederkofler EE, Tubbs KA, Kiernan UA, Nedelkov D, Nelson RW. Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins. J Lipid Res. 2003;44:630–9. [DOI] [PubMed]

17.

Badrnya S, Doherty T, Richardson C, McConnell RI, Lamont JV, Veitinger M, et al. Development of a new biochip array for APOE4 classification from plasma samples using immunoassay-based methods. Clin Chem Lab Med. 2018;56:796–802. [DOI] [PubMed]

18.

Ehara H, Yamamoto-Honda R, Kitazato H, Takahashi Y, Kawazu S, Akanuma Y, et al. ApoE isoforms, treatment of diabetes and the risk of coronary heart disease. World J Diabetes. 2012;3:54–9. [DOI] [PubMed] [PMC]

19.

Stavljenic-Rukavina A, Sertic J, Salzer B, Dumic M, Radica A, Fumic K, et al. Apolipoprotein E phenotypes and genotypes as determined by polymerase chain reaction using allele-specific oligonucleotide probes and the amplification refractory mutation system in children with insulin-dependent diabetes mellitus. Clin Chim Acta. 1993;216:191–8. [DOI] [PubMed]

20.

Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545–8. [DOI] [PubMed]

21.

Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer’s disease: progress to date and the path forward. Neuron. 2019;101:820–38. [DOI] [PubMed] [PMC]

22.

Husain MA, Laurent B, Plourde M. APOE and Alzheimer’s disease: from lipid transport to physiopathology and therapeutics. Front Neurosci. 2021;15:630502. [DOI] [PubMed] [PMC]

23.

Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K, et al.; Japanese Alzheimer’s Disease Neuroimaging Initiative; Sun CK, Beckett LA, Petersen RC, Weiner MW, Aisen PS, Donohue MC; Alzheimer’s Disease Neuroimaging Initiative. Japanese and North American Alzheimer’s disease neuroimaging initiative studies: harmonization for international trials. Alzheimers Dement. 2018;14:1077–87. [DOI] [PubMed]

24.

Veiga S, Rodríguez-Martín A, Garcia-Ribas G, Arribas I, Menacho-Román M, Calero M. Validation of a novel and accurate ApoE4 assay for automated chemistry analyzers. Sci Rep. 2020;10:2138. [DOI] [PubMed] [PMC]

25.

Palmqvist S, Stomrud E, Cullen N, Janelidze S, Manuilova E, Jethwa A, et al. An accurate fully automated panel of plasma biomarkers for Alzheimer’s disease. Alzheimers Dement. 2023;19:1204–15. [DOI] [PubMed] [PMC]

26.

Srivastava RAK. Regulation of the apolipoprotein E by dietary lipids occurs by transcriptional and post-transcriptional mechanisms. Mol Cell Biochem. 1996;155:153–62. [DOI] [PubMed]

27.

Janelidze S, Bali D, Ashton NJ, Barthélemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. Brain. 2023;146:1592–601. [DOI] [PubMed] [PMC]

28.

Nojima H, Ito S, Kushida A, Abe A, Motsuchi W, Verbel D, et al. Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE^® system. Ann Clin Transl Neurol. 2022;9:1898–909. [DOI] [PubMed] [PMC]

29.

Musso G, Cosma C, Zaninotto M, Gabelli C, Basso D, Plebani M. Pre-analytical variability of the Lumipulse immunoassay for plasma biomarkers of Alzheimer’s disease. Clin Chem Lab Med. 2023;61:e53–6. [DOI] [PubMed]